Sarepta’s accelerated approval last week of EXONDYS 51™ for the treatment of around 13% of DMD patients is a significant milestone in the DMD market. We believe this sets a precedent for companies such as Summit and its utrophin modulation programme. Ezutromid, Summit’s lead DMD programme, commenced a Phase II proof-of-concept trial (PhaseOut DMD) in the UK in June. The first muscle biopsy data is expected Q2/Q3 2017. We take the opportunity to assess Summit’s offering in the context of recent d ....
